ClinicalTrials.gg

Program

S-337395

A development code.

Its studies are mostly in Respiratory Syncytial Virus Infections, led by Shionogi.

Furthest: phase 2, since Oct 8, 20252 company-led studies, 1 open or runningNext primary completion: Dec 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogi21 open or runningphase 2since Oct 8, 2025Feb 13, 2024Dec 30, 2026phase 2 · NCT07214571

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06270511 · 50 enrolled · United States
  2. Oct 8, 2025Phase 2 study in Respiratory Syncytial Virus InfectionsNCT07214571 · 192 planned · United States, Argentina, Bulgaria and more

Ahead

  1. Dec 30, 2026Primary completion: phase 2 study in Respiratory Syncytial Virus InfectionsNCT07214571

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07214571Respiratory Syncytial Virus Infections · United States, Argentina, Bulgaria and more2RecruitingDec 30, 2026192
NCT06270511Healthy Volunteers · United States1CompletedMay 30, 202450

How it is read

Names in the registry

  • “S-337395”, 2 entries

Codes read as this program: S337395.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.